NIKKEI 225
27,493.42 -113.04 (-0.41%) HANG SENG
21,283.52 -15.18 (-0.07%) CRUDE OIL
78.38 -0.09 (-0.11%) GOLD FUTURES
1,885.90 -4.80 (-0.25%) DOW
33,949.01 -207.68 (-0.61%) BTC-GBP
19,041.66 -411.86 (-2.12%)
Genfit S.A. (GNFT)
After hours:
| Previous close | 4.5500 |
| Open | 4.6020 |
| Bid | 3.9000 x 4000 |
| Ask | 4.8900 x 800 |
| Day's range | 4.6020 - 4.6500 |
| 52-week range | 3.0200 - 5.0500 |
| Volume | |
| Avg. volume | 12,457 |
| Market cap | 229.251M |
| Beta (5Y monthly) | 1.28 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.1400 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Globe Newswire
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) January 30, 2023 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with liver diseases characterized by high unmet medical needs, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial. Under the liquidity contract GENFIT has with Crédit Industriel et Commercial, the following resources appeared on the
- Globe Newswire
GENFIT Announces 2023 Financial Calendar
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) January 24, 2023 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with liver diseases characterized by high unmet medical needs, today announced its provisional financial calendar for 2023. 2023 Financial Calendar February 28, 2023 Publication of revenue and cash position at December 31, 2022 April 13, 2023 Publication of Full Year 2022 financial
- Globe Newswire
GENFIT to Participate in Upcoming Investor Conferences
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) January 5, 2023 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with liver diseases characterized by high unmet medical needs, today announced that management will participate in upcoming investor conferences. Conference Details (non-exhaustive list): Corporate Access Events during the 41st JPMorgan Healthcare ConferenceDate: January 8 – 12, 202
